Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction

US12018032B2 · kind B2 · utility

Assignee

• BIOMEA FUSION, INC. · US

Inventors

• Priyanka Somanath · Dublin, US
• Daniel C. Lu · Los Angeles, US
• Taisei Kinoshita · San Mateo, US
• Brian Keith Law · Gainesville, US
• Thomas Butler · Redwood City, US
• James T. Palmer · San Ramon, US
• Nan-Horng Lin · Mundelein, US
• Heow Tan · Cupertino, US
• Angelina Sau Man Wong · Redwood City, US
• Siyi Jiang · Shanghai, CN
• Hongyan He · Shanghai, CN

Key dates

• Filing date: Aug 10, 2022
• Grant date: Jun 25, 2024
• Expiry date: Aug 10, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (I) including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include compound (I), as well as methods of using compound (I), alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.